Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease

Selecting the right dose is a significant challenge in designing clinical development programs, especially for slowly progressing diseases lacking predictive biomarkers of efficacy that may require long‐term treatment to assess clinical benefit. Gantenerumab, a fully human monoclonal antibody (mAb)...

Descripción completa

Detalles Bibliográficos
Autores principales: Retout, Sylvie, Gieschke, Ronald, Serafin, Daniel, Weber, Cornelia, Frey, Nicolas, Hofmann, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313867/
https://www.ncbi.nlm.nih.gov/pubmed/35100444
http://dx.doi.org/10.1002/cpt.2535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313867/
https://www.ncbi.nlm.nih.gov/pubmed/35100444
http://dx.doi.org/10.1002/cpt.2535

Ejemplares similares